Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RenovoRx (RNXT) Cash & Equivalents (2024 - 2025)

RenovoRx (RNXT) has disclosed Cash & Equivalents for 2 consecutive years, with $7.0 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 1.82% to $7.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.0 million through Dec 2025, down 1.82% year-over-year, with the annual reading at $7.0 million for FY2025, 1.82% down from the prior year.
  • Cash & Equivalents hit $7.0 million in Q4 2025 for RenovoRx, down from $10.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $14.6 million in Q1 2025 to a low of $4.4 million in Q1 2024.